Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7)

References

• Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 2010; 16:186 - 93; PMID: 20216421
   PubMed Web of Science ®Google Scholar
• Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 2009; 30:769 - 82, ix; http://dx.doi.org/10.1016/j.ccm.2009.08.009; PMID: 19925966
   PubMed Web of Science ®Google Scholar
• Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology 2010; 15:433 - 50; http://dx.doi.org/10.1111/j.1440-1843.2010.01739.x; PMID: 20415982
   PubMed Web of Science ®Google Scholar
• Doherty TM. Immunotherapy for TB. Immunotherapy 2012; 4:629 - 47; http://dx.doi.org/10.2217/imt.12.52; PMID: 22788130
   PubMed Web of Science ®Google Scholar
• Prabowo SA, Gröschel MI, Schmidt EDL, Skrahina A, Mihaescu T, Hastürk S, et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013; 202:95 - 104; http://dx.doi.org/10.1007/s00430-012-0278-6; PMID: 23143437
   PubMed Web of Science ®Google Scholar
• Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004; 9:1701 - 19; http://dx.doi.org/10.2741/1292; PMID: 14977580
   PubMed Web of Science ®Google Scholar
• Boenickse R, Juhasz E. Beschreibung der neuen species Mycobacterium vaccae n.sp. Zentralbl Bakteriol Orig 1964; 192:133 - 5; PMID: 14176844
   PubMedGoogle Scholar
• von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, et al, DarDar Study Group. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24:675 - 85; http://dx.doi.org/10.1097/QAD.0b013e3283350f1b; PMID: 20118767
   PubMed Web of Science ®Google Scholar
• Dalgleish AG. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 2011; 29:8501 - 5; http://dx.doi.org/10.1016/j.vaccine.2011.09.012; PMID: 21933695
   PubMed Web of Science ®Google Scholar
• Hale MW, Rook GA, Lowry CA. Pathways underlying afferent signaling of bronchopulmonary immune activation to the central nervous system. Chem Immunol Allergy 2012; 98:118 - 41; http://dx.doi.org/10.1159/000336505; PMID: 22767061
   PubMedGoogle Scholar
• Yang XY, Chen QF, Li YP, Wu SM. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One 2011; 6:e23826; http://dx.doi.org/10.1371/journal.pone.0023826; PMID: 21909406
   PubMed Web of Science ®Google Scholar
• Luo Y, Lu S, Guo S. [Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 2000; 23:85 - 8; PMID: 11778496
   PubMedGoogle Scholar
• de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev 2003; 1:CD001166; PMID: 12535403
   PubMedGoogle Scholar
• Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, et al, LUSKAR collaboration. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002; 360:1050 - 5; http://dx.doi.org/10.1016/S0140-6736(02)11141-X; PMID: 12383985
   PubMed Web of Science ®Google Scholar
• Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354:116 - 9; http://dx.doi.org/10.1016/S0140-6736(98)10448-8; PMID: 10408487
   PubMed Web of Science ®Google Scholar
• Dlugovitzky D, Notario R, Martinel-Lamas D, Fiorenza G, Farroni M, Bogue C, et al. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis. Immunotherapy 2010; 2:159 - 69; http://dx.doi.org/10.2217/imt.09.90; PMID: 20635925
   PubMed Web of Science ®Google Scholar
• Wang W, Jin G, Ye Y, Xia X, Wang A, Zhuang Y, et al. [A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 1999; 22:108 - 10; PMID: 11820954
   PubMedGoogle Scholar
• Luo Y, National Cooperation Group On Clinical Study Of Mycobacterium Vaccae Vaccine. [The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 2001; 24:43 - 7; PMID: 11802939
   PubMedGoogle Scholar
• Johnson JL, Kamya RM, Okwera A, Loughlin AM, Nyole S, Hom DL, et al, The Uganda-Case Western Reserve University Research Collaboration. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. J Infect Dis 2000; 181:1304 - 12; http://dx.doi.org/10.1086/315393; PMID: 10753731
   PubMed Web of Science ®Google Scholar
• Bourinbaiar AS, Mezentseva MV, Butov DA, Nyasulu PS, Efremenko YV, Jirathitikal V, et al. Immune approaches in tuberculosis therapy: a brief overview. Expert Rev Anti Infect Ther 2012; 10:381 - 9; http://dx.doi.org/10.1586/eri.12.1; PMID: 22397570
   PubMed Web of Science ®Google Scholar
• Efremenko YV, Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Mospan IV, et al. Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patients. Immunotherapy 2012; 4:273 - 82; http://dx.doi.org/10.2217/imt.11.176; PMID: 22401633
   PubMed Web of Science ®Google Scholar
• Butov DA, Efremenko YV, Prihoda ND, Yurchenko LI, Sokolenko NI, Arjanova OV, et al. Adjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV. Immunotherapy 2012; 4:687 - 95; http://dx.doi.org/10.2217/imt.12.59; PMID: 22853755
   PubMed Web of Science ®Google Scholar
• McConkey B, Situnayake RD. Effects of rifampicin with and without isoniazid in rheumatoid arthritis. J Rheumatol 1988; 15:46 - 50; PMID: 3351840
   PubMed Web of Science ®Google Scholar
• Arjanova OV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, et al. Jirathitikal Vichai, Bourinbaiar AS, Frolov VM, Kutsyna GA. One-month immunotherapy trial in treatment-failed TB patients. Open J Immunol 2011; 1:50 - 5; http://dx.doi.org/10.4236/oji.2011.12006
   Google Scholar
• Arjanova OV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, et al. Therapeutic vaccination of treatment-failed TB patients on “palliative” support consisting of isoniazid and rifampicin. Mycobact Dis 2012; S1 - 001
   Google Scholar
• Yang XY, Chen QF, Cui XH, Yu Y, Li YP. Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: a meta-analysis. J Infect 2010; 60:320 - 30; http://dx.doi.org/10.1016/j.jinf.2010.02.005; PMID: 20156481
   PubMed Web of Science ®Google Scholar
• NIH Policy for Data and Safety Monitoring. . NIH Guide Grants Contracts1998; 12; http://grants.nih.gov/grants/guide/notice-files/not98-084.htm.
   Google Scholar